Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURVENT: Furmonertinib vs Chemotherapy in First-Line NSCLC with EGFR Exon 20 Insertion Mutations
NCT05607550Phase 3Active, not recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Jun 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by ArriVent BioPharma. Primary endpoint: Progression Free Survival at 32 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05607550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607550.